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Abstract
Background: The aim of this study was to investigate cytochrome P450 2C8*2 (CYP2C8*2) distribution and allele
frequency in three populations from West and East Africa exposed to Plasmodium falciparum malaria. CYP2C8
enzyme is involved in the metabolism of the anti-malarials amodiaquine and chloroquine. The presence of the
CYP2C8*2 defective allele has been recently associated to higher rate of chloroquine-resistant malaria parasites.
Methods: A total of 503 young subjects were genotyped for the single nucleotide polymorphism rs11572103 (A/T).
Eighty-eight were from southern Senegal, 262 from eastern Uganda and 153 from southern Madagascar. The PCR-
RFLP technique was used to discriminate the wild-type (A) from the defective allele (T).
Results: A CYP2C8*2 (T) allele frequency of 0.222 ± 0.044 was detected in Senegal, 0.105 ± 0.019 in Uganda and
0.150 ± 0.029 in Madagascar.
Conclusions: This study demonstrated that CYP2C8*2 allele is widespread in Africa. This allele occurs at different
frequency in West and East Africa, being higher in Senegal than in Uganda and Madagascar. These data indicate
that an important fraction of the populations analysed has a decreased enzymatic activity, thus being at higher risk
for drug accumulation with two possible consequences: i) an exacerbation of drug-associated adverse side effects;
ii) an increase of drug-resistance selection pressure on P. falciparum parasites.
Keywords: CYP2C8 enzyme, CYP2C8*2 allele, Plasmodium falciparum malaria, Africa, Poor metabolizers, Chloroquine,
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Background
Plasmodium falciparum malaria is one of the most
important infectious diseases in the developing world,
representing a priority in public health mainly in sub-
Saharan Africa. Nowadays, anti-malarial strategies
include: the development of a vaccine, the vector con-
trol, as well as drug treatment, which remains the most
effective remedy to clear the infection. However, the
spread of anti-malarial drug-resistance affects the out-
come of treatments [1], since P. falciparum has selected
resistant strains for the majority of the molecules used
in anti-malarial therapy [2]. As recently demonstrated,
host genetic variation in drug metabolizing enzymes
influences the selection of P. falciparum drug-resistance
in Burkina Faso [3]. In particular, the cytochrome P450
2 C8 (CYP2C8), a polymorphic enzyme that mainly con-
tributes to the hepatic metabolism of amodiaquine (AQ)
and chloroquine (CQ), shows a genetic variant
(CYP2C8*2)t h a ti sa s s o c i a t e dw i t hh i g h e rr a t eo fd r u g -
resistant parasites in the infected host (pfcrt-76Y and
pfmdr1-86Y P. falciparum alleles) [3].
CYP2C8 is a member of the human CYP2C enzyme
family, which also includes CYP2C9, CYP2C18 and
CYP2C19, whose genes are located on the chromosome
10q24 [4]. Human CYP2C8 is involved in the metabo-
lism of a variety of clinically important drugs, including
the anti-malarials AQ, CQ and, to a lesser extent, dap-
sone (DDS) [4]. CYP2C8 is the only enzyme involved in
the biotransformation of AQ [4], whereas for CQ it
plays a major role [5,6], the secondary routes for CQ
metabolism being limited by genetic and inhibitory fac-
tors in Africans [3,5-11]. CYP2C8 gene is known to be
polymorphic, and the distribution of variant alleles
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variant most common in Africans, is related to a poor
metabolizer phenotype (PM) in subjects carrying at least
one copy of the defective allele [4,9]. Subjects who are
poor metabolizers experience a longer drug half-life [12]
and have increased adverse side effects. In particular,
CYP2C8*2 shows six fold lower intrinsic clearance of
AQ than wild type [12]. On the other hand, no evidence
is yet available from the literature about the role of
CYP2C8 genetic variance in CQ pharmacokinetics [13],
although there is indirect evidence of lower CQ metabo-
lism in CYP2C8*2-carriers shown through the associa-
tion between the allele and rates of CQ-resistant P.
falciparum parasites [3]. In humans, CQ concentrations
decline multi-exponentially and elimination at its initial
anti-malarial concentrations is relatively rapid. This
means that it usually persists for only a few days at con-
centrations sufficient to select resistant over sensitive
parasites (its window of selection). The poor metaboli-
zers obviously greatly extent these windows. A slower
metabolism of an anti-malarial drug leads to a longer
time of parasite exposure to a sub-therapeutic level of
the molecule, therefore acting as a further co-factor in
drug-resistance selection. Few studies had described the
CYP2C8*2 allele frequency in Africa, and the actual
knowledge of its distribution is incomplete all over the
continent. The prevalence of this allele is reported to be
13.9% in Zanzibar [5], whereas in Ghana it ranges
between 16.8% and 17.9% [14-16]. Two studies had been
conducted in Burkina Faso, the former showed a
CYP2C8*2 prevalence of 11.5% in the south of the coun-
try [12]. In the second study, sympatric ethnic groups
living in the central area of Burkina Faso were analysed:
the Fulani showed a prevalence of 9.9% and the Mossi-
Rimaibè group 23.7% [3]. Moreover, Dai et al. [17]
reported a value of 18% in African-Americans.
CYP2C8*2 is virtually absent in non-African populations
[17], as in Caucasians, where instead the poor metaboli-
zer allele is represented by CYP2C8*3, which is absent
or found at very low frequency in Africa [17].
Actually, the official policies for the treatment of
uncomplicated forms of P. falciparum malaria are based
on artemisinin combination therapy (ACT), including
the association of artesunate with AQ. However, CQ is
still used as anti-malarials in several African countries
[18-22]. Moreover, the CQ tablets are often of poor
quality [23,24] and the compliance to the therapy is low
and then the selective effects on parasite are improved.
T h ea i mo ft h es t u d yw a st od e s c r i b et h ed i s t r i b u t i o n
of CYP2C8*2 in Senegal, Uganda and Madagascar, areas
that were not investigated by previous studies and char-
acterized by different levels of P. falciparum malaria
transmission intensity.
Methods
Study area and subjects
The samples analysed in the present study were col-
lected during cross-sectional surveys performed during
2007 in Senegal (Thionck Essyl health centre - Casa-
mance region); Uganda (Namalu and Rupa health cen-
tres, Kakoliye and Nadunget primary schools -
Karamoja region; Makindiye children centre - Kampala
region); and Madagascar (Amboasary, Antsanomaro,
Masihanaka and Fort Dauphin health centres - Anosy
region) (Figure 1). A total of 503 children and adoles-
cents had been enrolled: 88 were from Senegal (mean
age in years ± SD = 10.4 ± 3.5); 262 from Uganda
(mean age 7.8 ± 3.0) and 153 from Madagascar (mean
age 6.0 ± 4.1). For the purpose of the study were con-
sidered only unrelated individuals according to differ-
ent family names and interviews. The same protocol
for enrollment was followed in all sites [25,26]. Signed
informed consent for multiple genetic and epidemiolo-
gic surveys was obtained from the subjects or their
parents/caregivers [25,26]. This study was conducted
with the approval of the ethics committee and research
committee of the Sapienza University of Rome. Finger-
pick blood samples were spotted on Whatman grade 1
f i l t e rp a p e r sa tt h et i m eo ft h ef i e l ds u r v e ya n dt h e n
air dried before being separately stored in sealed plas-
tic containers.
Figure 1 Study areas.
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Human DNA was extracted with Chelex-100 resin (Bio-
Rad). CYP2C8*2 (rs11572103, A > T) detection was car-
ried out using the PCR-RFLP technique. Two μlo f
D N At e m p l a t ew e r eu s e dt oa m p l i f yb yP C Ra1 0 7b p
fragment of the CYP2C8 gene (forward primer: 5’-GAA-
CACCAAGCATCACTGGA-3’; reverse primer: 5’-
GAAATCAAAATACTGATCTGTTGC-3’); the PCR
product was then incubated with BclI enzyme that cuts
the wild-type allele only (A); undigested products repre-
sent the variant allele (T). To detect the size polymorph-
isms, the samples were ran on a Metaphor 3% gel.
Controls for human genotyping were utilized after
sequencing of the PCR product obtained from each dif-
ferent genotype. Moreover, to avoid genotyping error,
the analysis was repeated for all the heterozygous
samples.
Statistical analysis
Inter-populations comparisons were obtained by Yates-
corrected c
2 test and by Mantel-Haenszel c
2 test (M-H).
Odds ratios (ORs) were calculated with 95% confidence
intervals (CIs). The analyses were performed with epi
info 6 statistical package. GenePop software was used
for the evaluation of hardy-Weinberg equilibrium [27].
Results
The frequencies of the CYP2C8*2 allele for each country
included in the present study are reported in Table 1.
Genotype frequencies were in Hardy-Weinberg equili-
brium both for Uganda and Madagascar (c
2 =1 . 5 2 ,P =
0.221 and c
2 = 2.61, P = 0.106, respectively), while an
excess of AT heterozygotes was found for Senegal (c
2 =
7.11, P = 0.008), probably because of the small sample
size (N = 88). Comparing the allele frequency among
the populations studied, a statistically significant differ-
ence was found between Senegal and Uganda (OR =
2.43, 95% CI 1.51-3.91; Yates-corrected c
2 = 14.43, P =
0.0001; M-H c
2 = 15.49, P < 0.0001) whereas a lower
difference was revealed in the other comparisons (Sene-
gal vs Madagascar: OR = 1.85, 95% CI 1.11-3.10; Yates-
corrected c
2 =5 . 6 2 ,P = 0.0177; M-H c
2 =6 . 2 3 ,P =
0.0126; Madagascar vs Uganda: OR = 0.76, 95% CI 0.48-
1.20; Yates-corrected c
2 =1 . 2 4 ,P = 0.2654; M-H c
2 =
1.50, P = 0.2201). Furthermore, the percentage of sub-
jects carrying at least one copy of the CYP2C8*2 allele
(T) was 44.3%, 20.6% and 26.1% for Senegal, Uganda
and Madagascar, respectively.
Discussion
The discovery of functional variability in genes encoding
drug metabolizing enzymes has contributed significantly
to the understanding of the inter-individual variability in
dose-concentration relationships and drug response.
Knowledge of polymorphisms in genes encoding
enzymes that metabolize anti-malarial drugs, as well as
their associations with clinical and parasitological out-
comes, can be useful in designing dosage regimens and
modulating drug therapy that is safe, effective and there-
fore less likely to select for pathogen’s drug resistance.
This work describes the distribution of the African
defective allele CYP2C8*2, whose corresponding enzyme
is an important player in the metabolism of two wide-
spread anti-malarial compounds, CQ and AQ. The allele
frequencies of CYP2C8*2 observed in the three different
populations are partially in agreement with other data
available in the literature. In particular, the allele fre-
quency found in Uganda (10.5%) is in line with that
reported from Zanzibar (13.9%), to date the only other
study conducted in East Africa [9]. In Uganda, the Kara-
moja region and the suburban districts of the capital
Kampala are areas of hyper-endemic malaria transmis-
sion [28], where anti-malarial treatment is based on
ACT, mainly a combination of artemether and lumefan-
trine (AL) and, as an alternative, artesunate (AS) plus
AQ [28]. Consequently, the presence of the CYP2C8*2
allele may be a potential co-factor in the onset of
a d v e r s es i d ee f f e c t sa s s o c i a t ed with AQ administration.
Furthermore, as there is evidence that both pfcrt and
pfmdr1 parasite resistant alleles play a role in AQ-resis-
tance [29], it could emerge the risk related to the pre-
sence of CYP2C8*2 in selecting AQ- resistant strains,
since the interplay between host and parasite genetic
variation could be similar to that of CQ.
No data of CYP2C8 polymorphisms in Madagascar are
available in the literature. Here it is reported a non-neg-
ligible frequency of 26.1% of CYP2C8*2-carriers in an
area of low malaria transmission, where CQ was still
Table 1 CYP2C8 genotypes and T allele frequency in three African populations
Countries CYP2C8 (rs11572103, A > T) frequencies
Relative and (absolute) genotype frequencies Allele frequency ± SE
Sample N AA AT TT T
Senegal 88 0.557 (49) 0.443 (39) 0.000 (0) 0.222 ± 0.044
Uganda 262 0.797 (208) 0.199 (53) 0.004 (1) 0.105 ± 0.019
Madagascar 153 0.739 (113) 0.222 (34) 0.039 (6) 0.150 ± 0.029
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replaced by AS plus AQ combination therapy as the
first-line treatment for uncomplicated cases since 2005
[30]. In Madagascar, P. falciparum CQ-resistance is
mainly based on pfmdr1-86Y rather than pfcrt-76Y
alleles [30,31]. Intriguingly, this setting is similar to that
previously reported from Burkina Faso, where the obser-
vation of CQ-resistance was mainly based on pfmdr1
polymorphism [3].
Concerning Senegal, the excess of AT heterozygotes
c o u l db ea t t r i b u t a b l et oas t o c h a s t i ce f f e c td u et ot h e
sampling, despite the efforts to avoid the enrolment of
related subjects. Nevertheless, a deviation of the geno-
type frequencies from the expected Hardy-Weinberg
proportions could be expected in discrete populations
[32]. The CYP2C8*2 allele frequency found in the Sene-
galese subjects (22.2%) is similar to that of Mossi-
Rimaibè from Burkina Faso (23.7%) [3] and, in general,
the frequency of this allele is higher in West than in
East Africa, two-fold higher in Senegal than in Uganda,
as reported in this study.
Conclusions
Although malaria infection in Africa is associated with a
perverse cycle of disease and poverty that hampers most
eradication and control efforts, the study of pharmaco-
genetics of anti-malarial drugs in human populations
exposed to P. falciparum suggests that an early identifi-
cation of PM individuals could lead to alternative ther-
apy of selected individuals/groups in order to minimize
the adverse side effects (and therefore the compliance to
therapy) as well as delay the spread of drug-resistance.
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